New test could predict CAR t success in lymphoma patients
NCT ID NCT07472972
First seen Mar 26, 2026 · Last updated Jun 03, 2026 · Updated 6 times
Summary
This study aims to create a test that combines blood tests, scans, and immune system checks to predict which lymphoma patients will benefit from CAR T cell therapy. About 50 adults with relapsed or hard-to-treat B-cell lymphoma will be followed for three months after treatment. The goal is to see if the test can be completed successfully and accurately predict who achieves remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universityhospital Zurich, Department of Medical Oncology and Hematology
RECRUITINGZurich, Canton of Zurich, 8091, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.